pentoxifylline has been researched along with Acquired Immunodeficiency Syndrome in 12 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since an AIDS Clinical Trial Group study suggested that pentoxifylline (400 mg thrice daily) is safe in AIDS patients and decreases TNF mRNA levels in peripheral blood mononuclear cells (PBMC), a second cohort received 800 mg thrice daily for 8 weeks." | 2.68 | High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Ahlers, CM; Chapman, B; Dando, S; Dezube, BJ; Flexner, C; Korvick, JA; Lederman, MM; Mattiacci, MR; Spritzler, JG; Zhang, L, 1995) |
| " PTX in a dosage of 1." | 1.30 | The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production. ( Ackermans, M; Endert, E; Heijligenberg, R; Romijn, JA; Sauerwein, HP; Timmer, JG, 1998) |
| "Thus, macrophages from AIDS patients with disseminated MAC infection are deficient in their ability to release TNF alpha, and further inhibition by pentoxifylline may be detrimental." | 1.29 | Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. ( Nedunchezian, D; Sarai, A; Sathe, SS; Tsigler, D, 1994) |
| "Severe weight loss is a common manifestation of advanced infection with the human immunodeficiency virus." | 1.29 | Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. ( Landman, D; Sarai, A; Sathe, SS, 1994) |
| "In this study we treated groups of MAIDS-infected mice with combinations of pentoxifylline, an agent which increases cAMP and inhibits phosphodiesterases, and sodium meclofenamic acid, a PgE2 inhibitor." | 1.29 | Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. ( Ambrus, JL; Butsch, J; Chadha, KC; Mathur, N; Munschauer, F; Nakeeb, S; Satchidanand, SK; Stadler, I; Toumbis, C; Vladutiu, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (91.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Green, LA | 1 |
| Kim, C | 1 |
| Gupta, SK | 1 |
| Rajashekhar, G | 1 |
| Rehman, J | 1 |
| Clauss, M | 1 |
| Dezube, BJ | 2 |
| Lederman, MM | 1 |
| Spritzler, JG | 1 |
| Chapman, B | 2 |
| Korvick, JA | 2 |
| Flexner, C | 1 |
| Dando, S | 1 |
| Mattiacci, MR | 1 |
| Ahlers, CM | 2 |
| Zhang, L | 1 |
| Sathe, SS | 2 |
| Sarai, A | 2 |
| Tsigler, D | 1 |
| Nedunchezian, D | 1 |
| Landman, D | 1 |
| Pardee, AB | 1 |
| Beckett, LA | 1 |
| Novick, WJ | 1 |
| Chiurco, J | 1 |
| Kasdan, P | 1 |
| Ecto, LT | 1 |
| Santos, J | 1 |
| Márquez, M | 1 |
| Rivero, A | 1 |
| Salgado, F | 1 |
| Stadler, I | 1 |
| Chadha, KC | 1 |
| Nakeeb, S | 1 |
| Toumbis, C | 1 |
| Butsch, J | 1 |
| Mathur, N | 1 |
| Munschauer, F | 1 |
| Vladutiu, A | 1 |
| Satchidanand, SK | 1 |
| Ambrus, JL | 2 |
| Luke, DR | 1 |
| McCreedy, BJ | 1 |
| Sarnoski, TP | 1 |
| Bookout, JB | 1 |
| Johnston, AM | 1 |
| Lell, JE | 1 |
| Wiggan, EB | 1 |
| Bell, N | 1 |
| Limjuco, RA | 1 |
| Guthrie, KI | 1 |
| Paradowski, PT | 1 |
| Zeman, K | 1 |
| Heijligenberg, R | 1 |
| Romijn, JA | 1 |
| Ackermans, M | 1 |
| Endert, E | 1 |
| Timmer, JG | 1 |
| Sauerwein, HP | 1 |
| Smart, T | 1 |
| Lillie, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS[NCT00000646] | Phase 1 | 54 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pentoxifylline and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
[Pentoxifylline].
Topics: Acquired Immunodeficiency Syndrome; Animals; Autoimmune Diseases; Humans; Immunity, Cellular; Killer | 1995 |
2 trials available for pentoxifylline and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; beta 2-Microglobulin; Biopterins; Body Weight; CD4 Lymphocyte Co | 1995 |
Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-CD8 Ratio; DNA, Viral; Drug Therapy, Combination; Fem | 1993 |
9 other studies available for pentoxifylline and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents; Cells, Cultured; Chemokine CXCL10; Dos | 2012 |
Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Colony Count, Microbial; | 1994 |
Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cachexia; Humans; Male; Middle Aged; Pentoxifylline; Pilo | 1994 |
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Biopterins; Body Weight; CD4-Positi | 1993 |
[Pentoxifylline in patients with AIDS and oral aphthous ulcers].
Topics: Acquired Immunodeficiency Syndrome; Humans; Pentoxifylline; Stomatitis, Aphthous | 1994 |
Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Cells, Cultured; Disease Models, Animal; Male; Meclofen | 1994 |
The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug T | 1998 |
Inhibiting TNF to preserve lean body mass.
Topics: Acquired Immunodeficiency Syndrome; Body Mass Index; Humans; Pentoxifylline; Tumor Necrosis Factor-a | 1995 |
Pentoxifylline in treatment of acquired immunodeficiency syndrome?
Topics: Acquired Immunodeficiency Syndrome; Cyclic AMP; Humans; Interferon-alpha; Pentoxifylline | 1992 |